This study aimed at the preparation an devaluation of ¹⁷⁷Lu-CHX-A′′-DTPA-Bevacizumab for targeting VEGF over-expressing cancers. Bevacizumab conjugated top-NCS-Bn-CHX-A′′-DTPA was radio labeled with ¹⁷⁷Lu. The radio immuno conjugate characterized by SE-HPLC exhibited radiochemical purity of 98.0±0.6%. In vitro stability was retained upto 4 days at 37 °C. In vitro cell binding studies showed good uptake by VEGF expressing U937 tumor cells. Bio distribution studies inmelanoma model showed significant up take and retention of ¹⁷⁷Lu-CHX-A′′-DTPA-Bevacizumab in tumor with reduction in up take in presence of cold Bevacizumab confirming its specificity to VEGF.